Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PSB-202 by Qilu Puget Sound Biotherapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval
PSB-202 is under clinical development by Qilu Puget Sound Biotherapeutics and currently in Phase I for Marginal Zone B-cell Lymphoma....
PSB-202 by Qilu Puget Sound Biotherapeutics for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
PSB-202 is under clinical development by Qilu Puget Sound Biotherapeutics and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)....
PSB-202 by Qilu Puget Sound Biotherapeutics for Follicular Lymphoma: Likelihood of Approval
PSB-202 is under clinical development by Qilu Puget Sound Biotherapeutics and currently in Phase I for Follicular Lymphoma. According to...
PSB-202 by Qilu Puget Sound Biotherapeutics for Mantle Cell Lymphoma: Likelihood of Approval
PSB-202 is under clinical development by Qilu Puget Sound Biotherapeutics and currently in Phase I for Mantle Cell Lymphoma. According...
PSB-202 by Qilu Puget Sound Biotherapeutics for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
PSB-202 is under clinical development by Qilu Puget Sound Biotherapeutics and currently in Phase I for Chronic Lymphocytic Leukemia (CLL)....